MDR1-EXPRESSING CD4
Publication Title
J Immunother Cancer
Document Type
Article
Publication Date
11-1-2023
Keywords
Humans; Female; Breast Neoplasms; CD8-Positive T-Lymphocytes; Neoadjuvant Therapy; CD4-Positive T-Lymphocytes; Th17 Cells; Paclitaxel; Adaptive Immunity; CD4-Positive T-Lymphocytes; Lymphocytes, Tumor-Infiltrating; Tumor Biomarkers; Tumor Microenvironment; oregon; chiles
Abstract
BACKGROUND: Multidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cells, MDR1 is expressed by most CD8
METHODS: Phenotypic and functional characteristics of MDR1
RESULTS: MDR1
CONCLUSION: MDR1 favored the enrichment of Th1.17 and Th17 in blood and tumor after NAC that correlated to clinical response.
Area of Special Interest
Cancer
Area of Special Interest
Women & Children
Specialty/Research Institute
Oncology
Specialty/Research Institute
Pharmacy
DOI
10.1136/jitc-2023-007733 http
